OCUGEN, INC. Treasury Stock, Common, Value
OCUGEN, INC. (OCGN) had Treasury Stock, Common, Value of $48.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:TreasuryStockCommonValue · last filed 2026-08-06
- 2026-06-30: Treasury Stock, Common, Value $48.00K.
- 2026-03-31: Treasury Stock, Common, Value $48.00K.
- 2025-12-31: Treasury Stock, Common, Value $48.00K.
- 2025-09-30: Treasury Stock, Common, Value $48.00K.
| Period end | Treasury Stock, Common, Value |
|---|---|
| 2026-06-30 | $48.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $48.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $48.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $48.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $48.00K 10-Q · filed 2025-08-04 |
| 2025-03-31 | $48.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $48.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $48.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $48.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $48.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $48.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | $48.00K 10-K · filed 2024-04-16 |
| 2023-06-30 | $48.00K 10-K · filed 2024-04-16 |
| 2023-03-31 | $48.00K 10-K · filed 2024-04-16 |
| 2022-12-31 | $48.00K 10-K · filed 2024-04-16 |
| 2022-09-30 | $48.00K 10-K · filed 2024-04-16 |
| 2022-06-30 | $48.00K 10-K · filed 2024-04-16 |
| 2022-03-31 | $48.00K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |